Literature DB >> 15674420

Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.

M Pérez-Andrés1, J Almeida, M Martín-Ayuso, M J Moro, G Martín-Nuñez, J Galende, D Borrego, M J Rodríguez, F Ortega, J Hernandez, I Moreno, M Domínguez, G Mateo, J F San Miguel, A Orfao.   

Abstract

The immunological bone marrow (BM) microenvironment plays a major role in controlling growth and survival of clonal plasma cells (PC); this might translate into different patterns of expression of molecules involved in immune responses on PC from different types of monoclonal gammopathies (MG). We have studied the expression of a group of nine such molecules on both BMPC and the plasma of 61 newly diagnosed MG patients (30 MG of undetermined significance (MGUS), 27 multiple myeloma (MM) and four plasma cell leukemia (PCL)) and five normal individuals. Clonal PC from all MG displayed significantly increased levels of CD56, CD86 and CD126, and decreased amounts of CD38 (P<0.001). Additionally, HLA-I and beta2-microglobulin were abnormally highly expressed in MGUS, while CD40 expression was decreased in MM and PCL (P<0.05). Interestingly, a progressive increase in the soluble levels of beta2-microglobulin was found from MGUS to MM and PCL patients (P=0.03). In contrast, all groups showed similar surface and soluble amounts of CD126, CD130 and CD95, except for increased soluble levels of CD95 observed in PCL. Overall, those phenotypic differences are consistent with increased antigen presentation and costimulatory capacities in MGUS, which progressively deteriorate in malignant MG (MM and PCL).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674420     DOI: 10.1038/sj.leu.2403647

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  27 in total

Review 1.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

2.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Authors:  Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron
Journal:  Cytometry B Clin Cytom       Date:  2015-07-06       Impact factor: 3.058

3.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

Review 4.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

Review 5.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

Review 6.  Myelomagenesis: capturing early microenvironment changes.

Authors:  Neha Korde; Irina Maric
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 7.  Immunologic approaches for the treatment of multiple myeloma.

Authors:  Leo Rasche; Niels Weinhold; Gareth J Morgan; Frits van Rhee; Faith E Davies
Journal:  Cancer Treat Rev       Date:  2017-04-06       Impact factor: 12.111

8.  Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.

Authors:  Ludger Klewes; Rhea Vallente; Eric Dupas; Carolin Brand; Dietrich Grün; Amanda Guffei; Chirawadee Sathitruangsak; Julius A Awe; Alexandra Kuzyk; Daniel Lichtensztejn; Pille Tammur; Tiiu Ilus; Anu Tamm; Mari Punab; Morel Rubinger; Adebayo Olujohungbe; Sabine Mai
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

Review 9.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 10.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.